Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Cybin Inc (CYBN)

CBOE Canada
Symbol
Exchange
Currency
CYBNCBOE CanadaCAD
CYBNNYSEUSD
Currency in CAD
Disclaimer
0.52
+0.01(+1.96%)
Closed

CYBN Comments

love this stock it will be in much demand
Last week I was way-up on this dog don't bother with it.
Unfortunately little obscure stocks with big potential are at the mercy of greedy skimmers
I've seen this pattern before...skimmers...it'll never be the stock that it's capable of being because they skim off the top every time it goes over $1.00 don't bother with this inexpensive one.
🍄
http://crweworld.com/article/news-provided-by-business-wire/2225622/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003-for-the-treatment-of-major-depressive-disorder-and-alcohol-usen-disorder
what's with the big jump today
what's with the big jump today ?
Canadian investment bank Stifel GMP has released new research on psychedelics and both $FTRP and $CYBN Their research calls psychedelic medicines a "possible disruptor to legacy treatments" and shares their perspective that there is an "accelerating wave of psychedelic reform." CYBN was given a speculative buy rating and a $5 price target. The report can be found with a quick google search.
At this point, I'm not a fan of FTRP due to the fact that its trading on such low daily volume. Also, the Horizon ETF (PSYK) is about to launch and they might have been buying up CYBN on Friday. Not giving advice on what to do. Always do your own DD. Good luck!
This one is my favourite companies in this sector at the moment. One of the side effects of psilocybin mushrooms in higher dosages is mild nausea. Their sublingual film drug (psilotonin) which is about to enter phase 2a bypasses the stomach, liver etc. In other words, everyone else is working on pill formulations that have to be digested while these folks seem to have a brilliant product in the making. Anyone else here holding long? If so, what are your reasons for liking this one?
Holding long, MMED is at the fore front in this ground breaking industry. This is just the beginning. I predict this stock to be + $10.00 within two years and + $20.00 after first FDA approval
 CYBN is undervalued compared to its peers imo and I have a feeling that people are sleeping on this one. If you haven't read over their investor presentations, I highly recommend going to view them on their website. Keep in mind that these drugs are going to be used in clinics with psychotherapy integration to help the patients find what they really need to take away from their mystical experience in order to heal their depression and regain control of their lives. Just my opinion here, everyone must do their own DD. Good luck!
yes, bought some for $2.22
not looking so great now is it,
 sold @ 2.32. now looking to enter @ 1.66
Any holders here?
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.